《內房》標普料萬科(02202.HK)全年合約銷售額跌四成 重申「B-」信貸評級 剔出觀察名單
標普全球評級發表報告,重申對萬科(02202.HK)的「B-」長期發行人評級,展望「負面」兼剔出觀察名單,料集團今年全年的合約銷售額將按年跌40%至1,460億元人民幣(下同),並料集團列賬經營現金流將難以達至盈虧平衡。為了維持流動性,標普認為萬科未來一年將維持最低限度土地購買,但將會削弱其競爭地位。而大股東深圳地鐵年初至今已提供近150億元貸款,該行認為集團已用這筆款項償還部分債券。
截至今年3月,該行料萬科仍有約140億元的未收回資產處置款項,亦估計集團有180億元可用現金。為了進一步提高流動性,相信公司將尋求機會加強處置非核心資產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.